Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugemalimab Consolidation Therapy in Limited-stage Small-cell Lung Cancer
NCT05623267Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2023
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sugemalimab in small cell lung cancer (SCLC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free Survival at 36 months. Started Jul 2023; status: recruiting.
02
Drugs
sugemalimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05623267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05623267.